| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.00B | 20.10B | 19.46B | 17.97B | 17.42B | 16.47B |
| Gross Profit | 12.11B | 12.11B | 11.25B | 10.15B | 10.29B | 9.93B |
| EBITDA | 4.80B | 4.85B | 4.25B | 3.37B | 3.76B | 4.35B |
| Net Income | 2.91B | 2.89B | 2.30B | 1.78B | 2.17B | 2.69B |
Balance Sheet | ||||||
| Total Assets | 17.47B | 16.05B | 16.39B | 15.73B | 15.04B | 15.92B |
| Cash, Cash Equivalents and Short-Term Investments | 1.22B | 1.10B | 966.00M | 775.00M | 832.00M | 888.00M |
| Total Debt | 8.76B | 8.51B | 9.06B | 9.27B | 7.83B | 8.21B |
| Total Liabilities | 16.42B | 15.50B | 15.44B | 14.93B | 14.07B | 14.82B |
| Stockholders Equity | 702.00M | 212.00M | 609.00M | 401.00M | 609.00M | 743.00M |
Cash Flow | ||||||
| Free Cash Flow | 3.37B | 3.55B | 3.04B | 1.86B | 2.76B | 3.31B |
| Operating Cash Flow | 3.92B | 4.11B | 3.75B | 2.56B | 3.33B | 3.72B |
| Investing Cash Flow | -790.00M | -534.00M | -742.00M | -1.60B | -592.00M | -878.00M |
| Financing Cash Flow | -3.05B | -3.39B | -2.79B | -952.00M | -2.77B | -2.82B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $351.37B | 21.95 | 31.90% | 2.78% | 1.23% | 17.97% | |
| ― | $148.02B | 24.57 | 28.36% | 3.17% | -0.30% | -14.60% | |
| ― | $62.27B | 21.66 | 705.21% | 2.67% | 0.05% | 3.55% | |
| ― | $19.93B | 38.60 | 12.07% | 1.39% | 1.13% | -34.78% | |
| ― | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
| ― | $13.69B | 17.26 | 249.61% | 4.37% | 0.16% | 191.17% | |
| ― | $39.88B | 16.09 | 136.87% | 4.16% | -6.89% | 7.52% |
Colgate-Palmolive Company is a global leader in consumer products with a focus on Oral Care, Personal Care, Home Care, and Pet Nutrition, operating in over 200 countries with a commitment to sustainability and community wellbeing.
The recent earnings call for Colgate-Palmolive presented a mixed outlook, highlighting both significant achievements and ongoing challenges. While the company celebrated successes in innovation and strategic acquisitions, it also faced cost pressures and market softness, particularly in North America and Europe. Consumer cautiousness in these regions further tempered the overall sentiment.
On July 31, 2025, Colgate-Palmolive‘s Board of Directors approved a new three-year productivity program aimed at supporting its 2030 strategy. This program focuses on optimizing the company’s global supply chain, streamlining organizational structures, and reducing overhead costs, with projected pre-tax charges between $200 and $300 million over three years. The program is expected to enhance the company’s operational efficiency and strategic alignment, with most charges incurred by the end of 2028, potentially impacting stakeholders and market positioning.
The most recent analyst rating on (CL) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Colgate-Palmolive stock, see the CL Stock Forecast page.